These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9058534)
1. Human moricizine metabolism. I. Isolation and identification of metabolites in human urine. Richards LE; Pieniaszek HJ; Shatzmiller S; Page GO; Blom KF; Read JM; Davidson AF; Confalone PN Xenobiotica; 1997 Feb; 27(2):217-29. PubMed ID: 9058534 [TBL] [Abstract][Full Text] [Related]
2. Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites. Pieniaszek HJ; Davidson AF; Chaney JE; Shum L; Robinson CA; Mayersohn M Xenobiotica; 1999 Sep; 29(9):945-55. PubMed ID: 10548454 [TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of sulphoxidation metabolites of moricizine in rat and human biological fluids. Yang JM; Chan K Methods Find Exp Clin Pharmacol; 1995; 17(6):415-21. PubMed ID: 8642903 [TBL] [Abstract][Full Text] [Related]
4. Degradation kinetics and mechanisms of moricizine hydrochloride in acidic medium. King SP; Sigvardson KW; Dudzinski J; Torosian G J Pharm Sci; 1992 Jun; 81(6):586-91. PubMed ID: 1522500 [TBL] [Abstract][Full Text] [Related]
5. The effect of hepatic disease on the disposition of moricizine in humans. Pieniaszek HJ; Davidson AF; McEntegart CM; Quon CY; Sampliner RE; Mayersohn M Biopharm Drug Dispos; 1994 Apr; 15(3):243-52. PubMed ID: 7880984 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of moricizine in young patients. Rice PJ; LeClair IO; Stone WL; Mehta AV J Clin Pharmacol; 1995 Oct; 35(10):1016-9. PubMed ID: 8568009 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, hemodynamic effects, and pharmacokinetics of high-dose moricizine during short- and long-term therapy. Salerno DM; Sharkey PJ; Granrud GA; Asinger RW; Hodges M Clin Pharmacol Ther; 1987 Aug; 42(2):201-9. PubMed ID: 3301153 [TBL] [Abstract][Full Text] [Related]
11. Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias. Fitton A; Buckley MT Drugs; 1990 Jul; 40(1):138-67. PubMed ID: 2202581 [TBL] [Abstract][Full Text] [Related]
12. [Use of an anti-arrhythmia drug mexicord in the treatment of ventricular extrasystole]. Urumbaev RK; Suprunova IP; Imanakunova DSh; Rakhimova GR Kardiologiia; 1992 Mar; 32(3):48-50. PubMed ID: 1383590 [TBL] [Abstract][Full Text] [Related]
15. Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds. Pharand C; Goldman R; Fan C; Chow M; Kluger J Pacing Clin Electrophysiol; 1996 Jan; 19(1):82-9. PubMed ID: 8848382 [TBL] [Abstract][Full Text] [Related]
16. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Benedek IH; King SY; Powell RJ; Agra AM; Schary WL; Pieniaszek HJ J Clin Pharmacol; 1992 Jun; 32(6):558-63. PubMed ID: 1634644 [TBL] [Abstract][Full Text] [Related]
17. Clinical development of moricizine as an antiarrhythmic agent. Mahler SA; Borland RM Am J Cardiol; 1990 Feb; 65(8):11D-14D; discussion 68D-71D. PubMed ID: 2407088 [TBL] [Abstract][Full Text] [Related]
18. The metabolism of piperidine-type phenothiazine antipsychotic agents. III. Mesoridazine in dog, human and rat. Lin G; Hawes EM; McKay G; Korchinski ED; Midha KK Xenobiotica; 1993 Jan; 23(1):37-52. PubMed ID: 8097900 [TBL] [Abstract][Full Text] [Related]
19. Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia. Wyndham CR; Pratt CM; Mann DE; Winkle RA; Somberg J; de Maria AN; Josephson ME Am J Cardiol; 1987 Oct; 60(11):67F-72F. PubMed ID: 3310588 [TBL] [Abstract][Full Text] [Related]
20. Enzyme induction by moricizine: time course and extent in healthy subjects. Benedek IH; Davidson AF; Pieniaszek HJ J Clin Pharmacol; 1994 Feb; 34(2):167-75. PubMed ID: 8163717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]